Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Virginia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk: The Legacy of Informed Consent

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and the importance of informed consent. This legacy context established a baseline awareness of how therapeutic interventions carry both benefits and potential risks, empowering individuals to engage with healthcare decisions. Within this broad framework, the transition to a more specialized concern arises when a widely prescribed therapy becomes associated with a rare but serious adverse outcome. In the case of Tysabri, a medication used for certain chronic conditions, post-market surveillance and clinical experience have identified a link to progressive multifocal leukoencephalopathy (PML), a severe brain infection. This shift from general health literacy to a focused risk profile is particularly relevant for individuals who have been exposed to the drug and now face the medical and legal implications of such exposure. The occupational exposure concern here is not limited to healthcare workers handling the drug, but extends to patients who, through their treatment regimen, have been occupationally—in the sense of their patient role—exposed to a known hazard. Understanding the timeline for legal recourse, such as the statute of limitations in Virginia, becomes critical for those seeking accountability after a PML diagnosis. This pivot from general health awareness to specific exposure risk underscores the need for precise legal and medical guidance.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and is caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation can include progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis often requires brain imaging and cerebrospinal fluid analysis for JC virus DNA. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immune suppression in the brain allows latent JC virus to reactivate and cause infection. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must also be certified. Despite these precautions, PML cases have occurred, and the label notes that Tysabri also increases the risk of herpes encephalitis and meningitis, with serious and sometimes fatal cases reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri Claims in Virginia

For affected patients in Virginia, legal considerations involve the statute of limitations for filing a product liability claim. In Virginia, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. The label indicates that PML risk increases with longer treatment duration, especially beyond two years, but cases can occur earlier (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be gradual, and diagnosis can be delayed, which affects when the statute of limitations begins to run. Virginia courts apply the "discovery rule," meaning the clock starts when the patient knew or should have known of the injury and its possible cause. Adequacy of warnings is a central issue in such cases. The boxed warning clearly states the PML risk and identifies risk factors, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for vigilant monitoring, and the specific symptoms to watch for. The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient's PML was not detected early because monitoring was inadequate or symptoms were dismissed, this could form the basis of a claim that the warnings were insufficient or that the manufacturer failed to ensure proper risk communication. Attorney-related considerations for affected patients include the need to preserve medical records documenting Tysabri treatment dates, PML diagnosis, and any communications about risks. Patients should also document the timeline of symptoms and when they first suspected a link to Tysabri. Consulting with an attorney experienced in pharmaceutical litigation is advisable to assess the specific facts and determine whether the statute of limitations has been met. Given the severity of PML, which "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), prompt legal evaluation is important. In summary, Tysabri-associated PML is a serious adverse event with known risk factors and a defined clinical course. Virginia patients who develop PML should be aware of the two-year statute of limitations from discovery of the injury and should seek legal counsel to evaluate their case. The medical evidence underscores the importance of early detection and the role of adequate warnings in preventing harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this means the clock starts when the patient knew or should have known of the injury and its possible link to Tysabri. It is important to consult an attorney promptly to ensure the deadline is met.

What are the known risk factors for developing PML while on Tysabri?

The prescribing information identifies three specific risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating or continuing Tysabri therapy. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.